Literature DB >> 15843524

Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells.

Janneke N Samsom1, Lisette A van Berkel, Joop M L M van Helvoort, Wendy W J Unger, Wendy Jansen, Theo Thepen, Reina E Mebius, Sjef S Verbeek, Georg Kraal.   

Abstract

Mucosal tolerance prevents the body from eliciting productive immune responses against harmless Ags that enter the body via the mucosae, and is mediated by the induction of regulatory T cells that differentiate in the mucosa-draining lymph nodes (LN) under defined conditions of Ag presentation. In this study, we show that mice deficient in FcgammaRIIB failed to develop mucosal tolerance to OVA, and demonstrate in vitro and in vivo a critical role for this receptor in modulating the Ag-presenting capacity of dendritic cells (DC). In vitro it was shown that absence of FcgammaRIIB under tolerogenic conditions led to increased IgG-induced release of inflammatory cytokines such as MCP-1, TNF-alpha, and IL-6 by bone marrow-derived DC, and increased their expression of costimulatory molecules, resulting in an altered immunogenic T cell response associated with increased IL-2 and IFN-gamma secretion. In vivo we could show enhanced LN-DC activation and increased numbers of Ag-specific IFN-gamma-producing T cells when FcgammaRIIB(-/-) mice were treated with OVA via the nasal mucosa, inferring that DC modulation by FcgammaRIIB directed the phenotype of the T cell response. Adoptive transfer of CD4(+) T cells from the spleen of FcgammaRIIB(-/-) mice to naive acceptor mice demonstrated that OVA-responding T cells failed to differentiate into regulatory T cells, explaining the lack of tolerance in these mice. Our findings demonstrate that signaling via FcgammaRIIB on DC, initiated by local IgG in the mucosa-draining LN, down-regulates DC activation induced by nasally applied Ag, resulting in those defined conditions of Ag presentation that lead to Tr induction and tolerance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843524     DOI: 10.4049/jimmunol.174.9.5279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

2.  Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.

Authors:  Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort
Journal:  Immunology       Date:  2007-04-26       Impact factor: 7.397

Review 3.  The function of Fcγ receptors in dendritic cells and macrophages.

Authors:  Martin Guilliams; Pierre Bruhns; Yvan Saeys; Hamida Hammad; Bart N Lambrecht
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

Review 4.  Dendritic cell control of tolerogenic responses.

Authors:  Santhakumar Manicassamy; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

5.  The effect of oral tolerance on the allergic airway response in younger and aged mice.

Authors:  Janette M Birmingham; Sangita Patil; Xiu-Min Li; Paula J Busse
Journal:  J Asthma       Date:  2013-01-09       Impact factor: 2.515

6.  A polymorphism in the coding region of Il12b promotes IL-12p70 and IL-23 heterodimer formation.

Authors:  Antonie Zwiers; Ivan J Fuss; Diana Seegers; Tanja Konijn; Juan J Garcia-Vallejo; Janneke N Samsom; Warren Strober; Georg Kraal; Gerd Bouma
Journal:  J Immunol       Date:  2011-02-14       Impact factor: 5.422

7.  Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus.

Authors:  Kaihong Su; Hengxuan Yang; Xinrui Li; Xiaoli Li; Andrew W Gibson; John M Cafardi; Tong Zhou; Jeffrey C Edberg; Robert P Kimberly
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1.

Authors:  Agnieszka Rynda; Massimo Maddaloni; Dagmara Mierzejewska; Javier Ochoa-Repáraz; Tomasz Maslanka; Kathryn Crist; Carol Riccardi; Beata Barszczewska; Kohtaro Fujihashi; Jerry R McGhee; David W Pascual
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Local immune regulation of mucosal inflammation by tacrolimus.

Authors:  Jolanda M van Dieren; Margaretha E H Lambers; Ernst J Kuipers; Janneke N Samsom; C Janneke van der Woude; Edward E S Nieuwenhuis
Journal:  Dig Dis Sci       Date:  2009-12-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.